Trial Profile

A phase I study of RYI-018 in healthy and non-alcoholic fibrotic liver disease (NAFLD) patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nimacimab (Primary)
Indications Non-alcoholic fatty liver disease
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

11 Jan 2017 According to a Bird Rock Bio media release, company received approval to initiate this study.
27 Oct 2016 According to Bird Rock Bio media release, company has submitted Clinical Trial Authorization to initiate this study.
27 Oct 2016 According to Bird Rock Bio media release, data from the SAD and MAD are anticipated to be available in Q1 2017 and Q4 2017 respectively.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com